Screener
Ironwood Pharmaceuticals IRWD Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Accrued research and development costs | 22 | (2,664) |
| Operating lease liabilities | (1,256) | (1,156) |
| Other liabilities | (528) | 3,856 |
| Net cash provided by operating activities | 63,397 | 4,886 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (33) |
| Net cash used in investing activities | — | (33) |
| Cash flows from financing activities: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ironwood Pharmaceuticals's operating cash flow?
- Ironwood Pharmaceuticals (IRWD) reported operating cash flow of $58.28M in Q2 2026.
- What is the long-term trend for Ironwood Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2024), Ironwood Pharmaceuticals's operating cash flow has grown at a -26.6% compound annual growth rate (CAGR), from $261.9M to $103.55M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Ironwood Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude